Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

21.30 -0.29 (-1.34%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Here's Why Apellis Pharmaceuticals Is Getting Hammered Today ↗

September 10, 2021

Conflicting clinical trial results for the company's lead candidate are to blame.

Via The Motley Fool

Why IVERIC Bio Shares Are Soaring Today ↗

September 10, 2021

IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Friday after Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported results from its Phase 3 DERBY and OAKS studies...

Via Benzinga

Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views ↗

September 10, 2021

Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53. The U.S....

Via Benzinga

Topics Stocks

Apellis Loses A Third Of Its Value; Are Its Mixed Results Enough To Win FDA OK? ↗

September 10, 2021

Apellis Pharmaceuticals reported mixed results for an eye-disease treatment, leading APLS stock to crash on Friday.

Via Investor's Business Daily

10 Biggest Price Target Changes For Friday ↗

September 10, 2021

Wells Fargo lowered the price target on General Motors Company (NYSE:

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Analyst Ratings For Apellis Pharmaceuticals ↗

July 08, 2021

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021 ↗

September 10, 2021

Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 10, 2021

Gainers IVERIC bio (NASDAQ:ISEE) stock increased by 65.36% to $14.37 during Friday's pre-market session. The company's market cap stands at $1.4 billion. T2...

Via Benzinga

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗

September 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

September 10, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). T2...

Via Benzinga

Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line ↗

September 10, 2021

Apellis Pharmaceuticals Inc's (NASDAQ: APLS) pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy (GA). Despite the mixed...

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

August 19, 2021

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021 ↗

August 19, 2021

Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ:

Via Benzinga

Recap: Apellis Pharmaceuticals Q2 Earnings ↗

August 09, 2021

Shares of Apellis Pharmaceuticals (NASDAQ:APLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 73.25% year...

Via Benzinga

Unusual Options Activity Insight: Apellis Pharmaceuticals ↗

July 08, 2021

Shares of Apellis Pharmaceuticals (NASDAQ:APLS) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $65.4. Sentiment...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

July 08, 2021

DA Davidson lowered the price target for WD-40 Company (NASDAQ:

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

July 02, 2021

Credit Suisse raised the price target for Capital One Financial Corporation (NYSE:

Via Benzinga

The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures ↗

July 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders ↗

July 01, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...

Via Benzinga

The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO ↗

June 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗

June 25, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 14, 2021

Gainers RAPT Therapeutics (NASDAQ:RAPT) s...

Via Benzinga

The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts ↗

June 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗

June 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US ↗

June 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Agios Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements ↗

June 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗

June 01, 2021

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...

Via Benzinga

Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder Study ↗

May 25, 2021

Apellis Pharmaceuticals Inc (NASDAQ: APLS) and Swedish Orphan Biovitrum AB (SOBI) have reported positive top-line results from the Phase 3 PRINCE...

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

All News about Apellis Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today